Randomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images
Not Applicable
- Conditions
- Parkinson's Disease
- Registration Number
- JPRN-UMIN000019524
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria are following; 1) Patients with parkinsonism except Parkinson's disease 2) Patients with epilepsy 3) Patients with a history of surgery for PD within 6 months before screening 4) Patients treated with zonisamide, selegiline and/or pramipexole within 3 months before screening 5) Patients with any severe psychiatric symptoms, such as confusion, hallucination, delusion and abnormal behaviors 6) Patients with any histories of malignant syndrome 7) Patients with a history of drug allergy for zonisamide 8) Patients participating any other clinical studies (intervention) when screening 9, 10) Patients evaluated as unsuitable for participation in the study by physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method